Development of gastrointestinal GVHD.

Of the 143 placebo recipients and 145 fluconazole recipients who had gut GVHD data available, 95 (66%) placebo recipients and 88 (61%) fluconazole recipients had grade 0 gut GVHD, and 18 (13%) placebo recipients and 35 (24%) fluconazole recipients had grade 1 gut GVHD. Compared with placebo patients (open bars), patients who received fluconazole (solid bars) had significantly less severe gut GVHD develop (P = .019). Gut GVHD (x-axis) was graded according to published definitions.16